An investigational medicine in late-stage development by Jazz Pharmaceuticals hit the mark in treating cataplexy and excessive daytime sleepiness (EDS) in adults with narcolepsy. The drug also has the benefit of a lower sodium content, which is crucial due to narcolepsy’s association with an increased risk of comorbid conditions, including hypertension and cardiovascular disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,